miércoles, 14 de diciembre de 2016

Clinical Trials Update from NCI, December 12, 2016

Clinical Trials Update from NCI, December 12, 2016
National Cancer Institute banner

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
human breast tumor cells 

A phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for metastatic breast cancer ended early after a planned interim analysis showed a significant benefit in favor of the ribociclib arm.
Immune cells attacking a tumor 

The Food and Drug Administration (FDA) has approved an immunotherapy drug for some patients with non-small cell lung cancer and expanded the approval of another so that it is now available for more patients.

The FDA recently approved nivolumab (Opdivo®) for the treatment of squamous cell cancer of the head and neck. The approval was based on results of a randomized clinical trial that compared nivolumab with one of three standard therapies: cetuximab (Erbitux®), methotrexate, or docetaxel.
Clinical Trials Information for Patients and Caregivers

As patients think about taking part in a clinical trial, they will face the issue of how to cover the costs of care. Learn about the different types of costs and who is expected to pay for which costs in a cancer clinical trial.

Federal law requires most health insurance plans to cover routine patient care costs in clinical trials under certain conditions. Learn which types of trials are covered and specific costs that are not. 
NCI-Supported Clinical Trials that Are Recruiting Patients

In this study, men with high-risk prostate cancer that hasn't spread to other parts of the body will be treated with drugs that block the production and activity of the male hormone androgen. The purpose is to identify which men are most likely to benefit from the therapy before surgery to remove the prostate. This study is taking place at the NIH Clinical Center in Bethesda, Maryland.

This phase II study is for patients with metastatic non-small cell lung cancer that has an EFGR mutation. The purpose is to study whether local ablation may help a targeted therapy, osimertinib, work better.

This phase II trial is for people with ovarian, primary peritoneal, or fallopian tube cancer that has come back after treatment. The purpose is to study how well olaparib and cediranib maleate work in treating these cancers. 

No hay comentarios:

Publicar un comentario